The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.<\/p>\n
1058 ET \u2013 Eli Lilly is expanding the reach of its GLP-1 drugs internationally, a market with significant potential for the company especially as it launches its GLP-1 pill orforglipron. \u201cBased on results over the past several quarters, international demand for GLP-1s is running ahead of our expectations and LLY remains in a clear position of strength based on Mounjaro\u2019s superior profile and the upcoming launch of orforglipron,\u201d the analysts say. \u201c[International] Mounjaro sales are now annualizing to $12 billion despite what we view as a still highly underpenetrated market.\u201d Meanwhile, orforglipron, with its lower price and better scalability, has a significant opportunity internationally, the analysts say. (nicholas.miller@wsj.com<\/a>)<\/p>\n Copyright \u00a92025 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8<\/p>\n","protected":false},"excerpt":{"rendered":"The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET,…\n","protected":false},"author":2,"featured_media":161646,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[275],"tags":[7823,41563,41562,4556,41573,74053,93669,41570,13782,41564,41565,18,41571,3334,135,475,474,19,41586,17,93672,3865,24176,13248,4265,82482,93671,41561,9436,44285,93670,41585,26243,41580],"class_list":{"0":"post-161645","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-acquisitions","9":"tag-acquisitions-mergers","10":"tag-acquisitions-mergers-shareholdings","11":"tag-autism-spectrum-disorders","12":"tag-ce-industry-news-filter","13":"tag-consumer-goods","14":"tag-consumer-paper-products","15":"tag-content-types","16":"tag-corporate","17":"tag-corporate-actions","18":"tag-corporate-industrial-news","19":"tag-eire","20":"tag-factiva-filters","21":"tag-general-news","22":"tag-health","23":"tag-health-care","24":"tag-healthcare","25":"tag-ie","26":"tag-industrial-news","27":"tag-ireland","28":"tag-linkendrnrealtime-linkedarticle-dnco20251103011701","29":"tag-medical-conditions","30":"tag-mental-disorders","31":"tag-mergers","32":"tag-neurodevelopmental-disorders","33":"tag-newsplus","34":"tag-nondurable-household-products","35":"tag-ownership-changes","36":"tag-political","37":"tag-political-general-news","38":"tag-sanitary-paper-products","39":"tag-shareholdings","40":"tag-synd","41":"tag-wsj-pro-wsj-com"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/161645","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=161645"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/161645\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/161646"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=161645"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=161645"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=161645"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}